调脂复肝汤治疗非酒精性脂肪肝60例观察

目的观察调脂复肝汤治疗非酒精性脂肪肝的临床疗效。方法选取我院60例诊断为非酒精性脂肪肝的患者,按就诊先后顺序分为对照组和观察组,每组30例,对照组患者给予西药治疗,观察组患者在西药治疗的基础上给予调脂复肝汤治疗,观察两组患者的临床总体有效率、治疗前后肝功能指标变化、治疗前后血脂变化。结果观察组患者的临床总体有效率优于对照组(P0.05),两组患者治疗后肝功能指标水平较前明显改善,且观察组改善更明显(P0.05),与治疗前比较两组患者血脂水平明显降低,但组间比较差异无统计学意义(P0.05)。结论应用调脂复肝汤治疗非酒精性脂肪肝能够取得良好的临床疗效,明显改善肝功能,降低血脂水平,可在临床中推广应用。     

扶正消脂汤治疗非酒精性脂肪肝60例临床观察

目的：观察自拟扶正消脂汤治疗非酒精性脂肪肝的疗效。方法：治疗组用自拟扶正消脂汤治疗非酒精性脂肪肝60例,同时与对照组60例应用口服水飞蓟宾胶囊,比较两组疗效。蛄果：治疗组总有效率为90．00％,对照组总有效率为68．33％,两组比较。差异有显著性（P＜0．05）。结论：自拟扶正消脂汤治疗非酒精性脂肪肝有较好的疗效。     

肝脂消胶囊治疗非酒精性脂肪肝临床研究

目的 观察肝脂消胶囊治疗非酒精性脂肪肝的临床疗效和安全性,并探讨其治疗机制.方法 选择120例非酒精性脂肪肝,中医辨证属脾虚湿盛、痰热血瘀、阻滞脉络之证患者,随机分为治疗组60例,对照组60例.治疗组口服肝脂消胶囊,对照组口服东宝肝泰片,两组均治疗90 d.观察中医证候积分、肝功能、血脂及肝脏B超治疗前后变化.结果 治疗组临床证候总有效率为95.0%,两组比较P＜0.05.两组对降低患者的血脂、血清转氨酶及脂肪肝的影像学改变方面有明显的作用;治疗组在改善脂肪肝患者的症状及影像学改变等方面的作用优于对照组,P＜0.01.结论 肝脂消胶囊用于非酒精性脂肪肝的治疗,其主要机理为健脾化湿、清热化痰、活血通络,有较好的临床疗效,无明显毒副作用.     

消脂护肝胶囊治疗非酒精性脂肪肝82例

目的评价消脂护肝胶囊治疗非酒精性脂肪肝的临床疗效。方法对确诊为非酒精性脂肪肝的135例患者,随机分为治疗组82例和对照组53例。治疗组服用消脂护肝胶囊,对照组服用东宝肝泰片,疗程为12周。观察治疗前后临床症状、肝脏超声、肝功能及血脂的变化。结果治疗组总有效率为91．46％,对照组总有效率为79．24％,两组比较差异有统计学意义（P〈0．05）。结论消脂护肝胶囊治疗非酒精性脂肪肝的疗效强于东宝肝泰片,是治疗非酒精性脂肪肝的有效药物。     

化痰消脂汤治疗非酒精性脂肪肝痰瘀互结证临床研究

目的:观察化痰消脂汤治疗非酒精性脂肪肝属痰瘀互阻证的临床疗效。方法:将100例非酒精性脂肪肝属痰瘀互结证患者按随机数字表法随机分为治疗组和对照组。治疗组50例,给予化痰消脂汤治疗;对照组50例,给予阿托伐他汀钙片治疗。两组均以14 d为1个疗程。治疗4个疗程后观察两组患者症状、体征、肝功能、血脂变化,比较两组患者临床疗效及B超变化。结果:治疗组有效率为82.00%,对照组有效率为68.00%,两组比较差异有统计学意义(P0.05)。结论:化痰消脂汤治疗非酒精性脂肪肝属痰瘀互阻证疗效显著。     

消脂活血治疗非酒精性脂肪性肝炎的临床观察

目的 探讨中药消脂活血汤治疗非酒精性脂肪性肝炎的临床疗效.方法 治疗组(56例)给予中药消脂活血汤口服;对照组(48例)用肝泰乐片,烟酸肌醇酯片治疗.病程均8周,观察治疗后肝功能、血脂、B超的变化情况.结果 治疗组的临床治愈率、总有效率均显著高于对照组(P<0.01).结论 中药消脂活血汤有良好的降低血脂、改善肝功能的作用.     

消脂汤治疗非酒精性脂肪性肝病疗效观察

目的:探讨消脂汤治疗非酒精性脂肪性肝病的临床疗效及机理.方法:选择80例非酒精性脂肪性肝病患者,随机均分为2组,对照组20例采取常规治疗,治疗组20例在常规治疗基础上加用消脂汤(药用苍术、白术、半夏、黄芩、厚朴等).观察治疗前后丙氨酸转移酶、门冬氨酸转移酶、谷氨酸转肽酶、胆固醇、甘油三酯等指标变化.结果:消脂汤治疗组患者丙氨酸转移酶、门冬氨酸转移酶、谷氨酸转肽酶、胆固醇、甘油三酯等指标明显优于对照组.结论:消脂汤治疗非酒精性脂肪性肝病临床疗效显著,对于患者预后具有积极意义.     

中医药治疗非酒精性脂肪肝的疗效及对肝脏CT值的影响

目的探讨中药疏肝消脂方治疗非酒精性脂肪肝的疗效及治疗前后肝脏CT影像学差异。方法 60例确诊为非酒精性脂肪肝患者随机分为治疗组和对照组,每组30例,对照组患者给予调节饮食结合适当运动进行治疗,治疗组在此基础上服用疏肝消脂方,分析比较治疗后3个月后两组CT、临床及生化指标变化情况。结果治疗组临床治疗总有效率93.33%,对照组86.67%,两组比较差异有统计学意义(P0.05);治疗后,与对照组相比,治疗组ALT、AST、TC及TG等肝功能各项指标均有所改善,差异有统计学意义(P0.05);与治疗前比较,治疗组肝CT值及肝/脾CT比值均升高,差异有统计学意义(P0.05);治疗后与对照组相比,治疗组肝CT值及肝/脾CT比值均升高,差异有统计学意义(P0.05)。结论疏肝消脂方治疗非酒精性脂肪肝疗效显著,CT定量技术评估中医药治疗非酒精性脂肪肝疗效方法安全、准确。     

复方消脂安肝方治疗非酒精性脂肪肝疗效观察

随着人们膳食结构和生活方式的改变,我国非酒精性脂肪性肝病(NAFLD)的发病率持续上升.我院运用复方消脂安肝方(消脂安肝汤联合减量黄连素)治疗非酒精性脂肪性肝病120例,疗效显著,总结报告如下.     

保肝消脂方治疗肝郁脾虚型非酒精性脂肪肝临床疗效观察

目的探讨“保肝消脂方”治疗非酒精性脂肪肝的临床疗效.方法将62例非酒精性脂肪肝患者随机分为2组,治疗组给予“保肝消脂方”联合血脂康治疗,对照组给予血脂康治疗,疗程均为8周,观察2组患者临床症状、肝功能、B超的变化.结果治疗组治疗8周后治愈8例,显效13例,有效5例,无效4例,总有效率86.67%.对照组治愈3例,显效9例,有效12例,无效8例,总有效率75.00%.两组疗效比较差异有统计学意义(P<0.05).结论“保肝消脂方”联合血脂康治疗非酒精性脂肪肝疗效优于单用血脂康.     

Liver

<正>209293 Probing into indication of living-related Liver Transplantation for Wilson’s disease/Cheng Feng(Liver Transplant Center,1st Hosp Nanjing Med Univ,Key Lab Living Donor Liver Transplant,Minist Public Health,Nangjing 210029)…∥Chin J Surg.-2009,47(6).-437~440Objective To probe into indication of living-related liver transplantation(LRLT)for Wilson’s Disease.Methods From January 2001 to February 2007,thirty-seven living-related liver transplants were performed.A retrospective analysis was carried on outcome of those patients.The indications for LRLT were acute hepatic failure in 3 patients and chronic advanced liver disease in 32 patients including 13 patients with Wilsonian neurological manifestations.Two patients presented with severe Wilsoian neurological manifestations even though their liver functions were stable.According to the scoring system for evaluation of the neurological impairment in Wilsion disease based on neurological signs and functions(total score was 30),the pre-transplantation score of those patients with neurological manifestations was 15.9±4.3(n=15).Results Thirty-seven patients were followed up for 20-93 months.The survival rates of post-transplant patients and grafts at 1,3,and 5 year were 91.9%,83.8%,75.7%,and 86.5%,78.4%,75.7%,respectivly.Postoperative surgical complications occurred in 2 donors with bile leakage required drainage,in 2 recipients with hepatic thormbosis underwent retransplantation of cadeveric liver and in 1 recipient with hepatic stenosis required balloon dilatation.Neurological function was improved in all recipients and the score of posttransplantation at 6,12,18,24,and 30 months was 17.5±3.7(n=13);21.0±4.3(n=12);23.9±3.9(n=10);26.6±2.2(n=10)and 28.1±1.9(n=7)respectively.Conclusion Patients with acute hepatic failure or patients with severe liver disease unresponsive to chelation tratment should be treated with LRLT.Early transplantation in patients with an unsatisfactory response medical tratment may prevent irreversible neurologica     

Liver

<正>209461 Intraoperative ligation of recipient’s portasystemic shunt in liver transplantation/Chen Litian(,Organ Transplant Center,Tianjin 1st Centr Hosp Tianjin 300192)…∥Chin J Gen Surg.-2009,25(4).-489～491Objective To investigate the clinical significance of ligating the portasystemic shunt confirmed by preoperative CT evaluation during orthotopic liver transplantation.Methods From January 2007 to August 2008,35 patients in Tianjin First Central Hospital underwent preoperative three-dimensional CT scan,among them 23 patients had spontaneous major portasystemic shunts,the other 12 patients did not have portasystemic shunts.16 out of the 23 cases with significant shunts underwent shunt ligation based on portal blood flow volume measured by intraoperative portal vein flowmetry.The shunt of the other 7 patients were left untreated.Results The portal blood flow in the 12 patients without portasystemic shunt judged by preoperative CT scanning were(1 101±70)ml/min.The shunts in 7 patients with portal blood flow greater than 1 000 ml/min were not ligated,that of the 16 patients with portal blood flow volume lower than 1 000 ml/min were ligated.The portal blood flow volume in those 16 patients before and after ligating the shunt were(657±112)ml/min and(1 136±161)ml/min,respectively(P<0.05).Postoperatively 2 patients suffered from portal vein thrombosis,among them 1 patients suffered from intermittent disturbance of consciousness,2 patients died within 3 months,with one died of respiratory failure from pulmonary aspergillus infection,one died of hepatic failure in 2 months after operation because of graft dysfunction.The other 19 patients with normal blood flow and well-functioning graft were alive.Conclusion The ligation of portasytemic shunt is mandatory in patients when pretransplant CT evaluation showing a major porto-systemic shunts and portal blood flow volume was less than 1 000 ml/min.5 refs,2 figs.     

Liver

Alleviation of ischemia-reperfusion injury in rat liver donors by induction of exogenous hTERT gene;Effects of surgical technique on acute renal failure after orthotopic liver transplantation in patients with end-stage liver disease at high risk： a report of 90 eases;Timing for liver transplantation for chronic severe hepatitis;Analysis of bacterial variance and drug resistance after orthotopic liver transplantation;The influence of splenectomy on orthotopic liver transplantation and its management     

Liver

Prevention and treatment of artery complication after liver transplantation by HBO , Clincal feature of cytomegabvirus pneumonia in orthtopic liver-transplantation and treatments, Risk factors of diabetes mellitus following orthotopic liver transplantation , Re-infection of hepatitis B virus after liver transplantation , Diagnosis and treatment of fungal infection after orthotopic liver transplantation , Two successful adult-to-adult living donor liver transplantation using dual grafts     

Liver

<正>209604 The suppressive effect of CD8+ CD28-regulatory T cells from spontaneous tolerance models on the acute rejection responses in rat liver transplantation/Chen Ning(陈宁,Dept Gastroenterol,Peking Univ Peop Hosp,Beijing 100044)…∥Chin J Organ Trans-plant. -2009,30(9). -524 ～526     

Liver

<正>209087 Clinical analysis of outcome of invasive fungal infection after kidney transplantation/Chen Guodong(陈国栋,Dept Transplant Surg,1st Hosp,Sun Yat sen Univ, Guangzhou 510080)…∥Chin J Organ Transplant. -2009, 30(10). -616～619 Objective To explore the outcome of invasive fungal infection in kidney transplantation and the influencing factors.     

探讨脂肪肝供肝在肝脏移植中的价值

目的探讨应用不同脂肪沉着程度供肝对肝移植患者预后的影响。方法选取64例进行肝移植术患者,依据供肝浸润程度,随机分为轻度脂肪肝组、中度脂肪肝组、重度脂肪肝组、无脂肪肝组共四组,每组各16例,比较四组患者肝功能(主要观察ALT、AST指标)、入住ICU的平均时间、1年移植物成活率、移植物原发无功发生率。结果轻度脂肪肝组入住ICU的平均时间、ALT和AST水平、移植物原发无功发生率与无脂肪肝组接近;中度脂肪肝组入住ICU平均时间、ALT和AST水平均较轻度组和无脂肪肝组明显增高,P0.05;重度脂肪肝组入住ICU平均时间、ALT和AST水平、移植物原发无功发生率明显较前三组为高,P0.05。结论轻、中度肝脏脂肪浸入可作为肝移植供肝,重度脂肪肝不能作为供肝的选择目标。     

Microenvironment of Liver Regeneration in Liver Cancer

The occurrence and development of liver cancer are essentially the most serious outcomes of uncontrolled liver regeneration. The progression of liver cancer is inevitably related to the abnormal microenvironment of liver regeneration. The deterioration observed in the microenvironment of liver regeneration is a necessary condition for the occurrence, development and metastasis of cancer. Therefore, the use of a technique to prevent and treat liver cancer via changes in the microenvironment of liver regeneration is a novel strategy. This strategy would be an effective way to delay, prevent or even reverse cancer occurrence, development and metastasis through an improvement in the liver regeneration microenvironment along with the integrated regulation of multiple components, targets, levels, channels and time sequences. In addition, the treatment of "tonifying Shen (Kidney) to regulate liver regeneration and repair by affecting stem cells and their microenvironment" can regulate "the dynamic imbalance between the normal liver regeneration and the abnormal liver regeneration"; this would improve the microenvironment of liver regeneration, which is also a mechanism by which liver cancer may be prevented or treated.     

化肝汤1号治疗酒精性肝纤维化症状及肝功能改变

目的观察活血化瘀、软坚散结药配伍治疗肝纤维化时对患者主、次症状改变及肝功能的影响。方法将确诊为酒精性肝纤维化患者90例,随机分为三组,治疗组采用自制方剂化肝汤1号(醋鳖甲、黄芩、柴胡、赤芍等),对照组1采用凯西莱治疗,对照组2采用化肝汤1号和凯西莱联合治疗,疗程3个月。观察三组患者治疗前后主、次症状改善情况,血清天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、γ谷氨酰转肽酶(γ-GT)变化。结果三组治疗后的临床疗效比较差异无统计学意义(H=2.5897,P>0.05)。三组治疗后肝功能指标均有改善,与治疗前比较,差异有统计学意义(P<0.05)。结论化肝汤1号可有效地降低肝细胞的损害程度,促进受损细胞修复,从而改善肝功能。